CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 142 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,822,941 | +12.3% | 994,161 | -17.5% | 9.80% | +13.4% |
| Q2 2023 | $13,195,298 | +10.5% | 1,205,050 | -12.0% | 8.65% | -13.2% |
| Q1 2023 | $11,945,763 | +15.2% | 1,369,927 | -17.1% | 9.96% | +11.1% |
| Q4 2022 | $10,367,414 | +27.4% | 1,653,495 | -28.9% | 8.97% | +22.1% |
| Q3 2022 | $8,140,000 | +6.5% | 2,325,833 | -10.2% | 7.34% | +12.8% |
| Q2 2022 | $7,640,000 | +76.9% | 2,589,679 | +86.5% | 6.51% | +62.3% |
| Q1 2022 | $4,318,000 | +4.3% | 1,388,505 | +13.4% | 4.01% | +11.0% |
| Q4 2021 | $4,140,000 | – | 1,224,968 | – | 3.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |